Research Paper Volume 12, Issue 19 pp 19316—19324
SYNE1 mutation may enhance the response to immune checkpoint blockade therapy in clear cell renal cell carcinoma patients
Somatic mutation, TMB and clinical outcomes in ccRCC patients. (A) Oncoplot for frequently mutated genes in ccRCC samples from TCGA cohort. Genes are listed by mutation frequency. The bottom panel shows the different mutation types. (B) TMB and clinical outcomes in ccRCC patients. X-tile plot of TMB and OS. A TMB score cutoff of 1.7 was used to divided patients into TMB-low and TMB-high subsets.